Is it safe for a patient with a history of bone marrow or stem cell transplantation and prior chemotherapy to receive the live‑attenuated yellow fever vaccine?

Yellow fever vaccine after bone marrow/stem cell transplant or chemotherapy

Do not give live‑attenuated yellow fever vaccine to patients with a history of hematopoietic stem cell/bone marrow transplant unless they are fully immune‑reconstituted off all immunosuppression and meet strict post‑transplant timing; otherwise, it is contraindicated and a medical waiver plus mosquito‑avoidance is safer. 1

• Framing (morbidity, mortality, QOL):
  • Live YF vaccine can cause fatal viscerotropic/neurotropic disease in immunocompromised hosts; preventing vaccine‑strain disease and severe wild‑type YF is the goal. Guideline consensus: generally avoid in immunocompromised patients; narrow exceptions exist mainly for certain HIV patients, and selected HSCT patients after immune reconstitution 1.

Algorithmic decision

1. Is the patient an HSCT/BMT recipient?

• Yes:
  • If <2 years post‑HSCT, on any immunosuppression, active/chronic GVHD, lymphopenia, or hypogammaglobulinemia: YF vaccine is contraindicated. Issue medical waiver; advise strict bite avoidance; consider itinerary change 1.
  • If ≥2 years post‑HSCT, off all immunosuppression, no GVHD, with evidence of immune reconstitution (normal/adequate CD4 and B‑cell function/Ig levels per local transplant protocol): YF vaccine may be considered case‑by‑case at specialized centers. Use a single 0.5 mL SC dose; document seroconversion if possible. This exception is supported by small, lower‑quality studies showing immunogenicity and no severe events, but data are limited; proceed only if travel is unavoidable and risks justify vaccination 1, 2. Pitfall: do not vaccinate earlier than immune reconstitution even if travel demands it.

1. No HSCT but prior chemotherapy for cancer:

• If currently immunosuppressed or within the period of significant chemotherapy‑induced immunosuppression: contraindicated; defer and provide waiver/avoidance 1.
• If chemotherapy completed and patient is now immunocompetent (e.g., ≥3 months after cytotoxic chemo, blood counts and lymphocyte subsets recovered, no ongoing immunosuppressants): YF vaccine can be given if travel risk warrants it. Use standard single 0.5 mL SC dose; consider post‑vaccination serology if concern for blunted response 1.

1. If vaccine cannot be given:

• Provide an official medical waiver (ICVP “medical contraindication” letter).
• Counsel on primary prevention: daytime and dusk mosquito avoidance (DEET/picaridin, permethrin‑treated clothing, screens/AC), choose non‑endemic routes/destinations, and ensure prompt fever evaluation.

Nuances and evidence strength

• Highest‑priority guideline: IDSA immunocompromised host vaccination guideline—YF vaccine generally should not be administered to immunocompromised persons; limited exceptions do not routinely include HSCT unless immune reconstitution is complete, and most live vaccines are avoided in HSCT until strict criteria are met 1.
• FDA label highlights HSCT recipients as a group that may need re‑dosing if previously vaccinated, implying use only after immune recovery; it does not endorse vaccination during immunosuppression 3.
• Research in HSCT shows small cohorts vaccinated years post‑transplant off immunosuppression achieved protection without serious events, but evidence is retrospective and limited; use only when unavoidable and criteria are met 2. Broader systematic reviews note rare but severe vaccine‑strain disease in immunosuppressed patients, reinforcing caution 4.

Practical checklist before considering YF vaccine post‑HSCT/chemo

• Off all systemic immunosuppression; no GVHD (HSCT only) 1.
• Adequate time since HSCT (generally ≥2 years) and since chemotherapy (generally ≥3 months) with documented immune reconstitution (e.g., CD4 recovery, normal IgG per local standards) 1.
• Travel is unavoidable to a YF‑endemic area with meaningful exposure risk.
• Administer single 0.5 mL SC dose; consider verifying neutralizing antibodies if feasible; monitor closely for adverse events 3.

Common pitfalls to avoid:

• Vaccinating HSCT recipients within 2 years, on immunosuppression, or with GVHD—high risk for severe adverse events 1.
• Assuming prior pre‑transplant vaccination still protects—protection may be lost post‑HSCT; reassess immunity 2.
• Ignoring safer alternatives (waiver, itinerary change, vector avoidance) when contraindicated.

Summary one‑liner for the chart:

• YF vaccine is contraindicated in immunocompromised patients including most HSCT recipients and those on/near chemotherapy; consider only after full immune reconstitution (HSCT typically ≥2 years, off IS, no GVHD) when travel is unavoidable; otherwise issue waiver and enforce vector precautions 1, 3.